KDR and neoplasm: Among the drugs in clinical trials for a second-line treatment, Ramucirumab has also been demonstrated to be effective in particular clinical conditions [10]; Ramucirumab is a direct VEGFR2 antagonist, binding VEGFR2 and blocking its interaction with natural VEGFR ligands (VEGF-A, VEGF-C, and VEGF-D), secreted by solid tumors to promote angiogenesis and enhance tumor blood supply [11].